Better Therapeutics (Better Therapeutics) Cash And Cash Equivalents : $6.60 Mil (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Better Therapeutics Cash And Cash Equivalents?

Better Therapeutics's quarterly cash and cash equivalents increased from Mar. 2023 ($6.07 Mil) to Jun. 2023 ($6.20 Mil) and increased from Jun. 2023 ($6.20 Mil) to Sep. 2023 ($6.60 Mil).

Better Therapeutics's annual cash and cash equivalents increased from Dec. 2020 ($0.12 Mil) to Dec. 2021 ($40.57 Mil) but then declined from Dec. 2021 ($40.57 Mil) to Dec. 2022 ($15.74 Mil).

Better Therapeutics Cash And Cash Equivalents Historical Data

The historical data trend for Better Therapeutics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Better Therapeutics Cash And Cash Equivalents Chart

Better Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Cash And Cash Equivalents

0.76

0.12

40.57

15.74

Better Therapeutics Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash And Cash Equivalents	Get a 7-Day Free Trial									22.31	15.74	6.07	6.20	6.60

Better Therapeutics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Better Therapeutics (OTCPK:BTTX) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Better Therapeutics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Better Therapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Better Therapeutics (Better Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Better Therapeutics Inc (OTCPK:BTTX) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

548 Market Street, Suite 49404, San Francisco, CA, USA, 94104

Website

https://www.bettertx.com

Better Therapeutics Inc is a prescription digital therapeutics company developing a novel form of cognitive behavioural therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions.

Executives

Elder Granger	director	5176 S. LEWISTON WAY, CENTENNIAL CO 80015
Mark A. Berman	officer: Chief Medical Officer	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Geoffrey M. Parker	director	15 RIORDAN PLACE, MENLO PARK CA 94025
Frank Karbe	director, officer: See Remarks	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David P Perry	director, 10 percent owner, officer: See Remarks	1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303
Andrew J. Armanino	director	C/O CALIFORNIA BANCORP, 1300 CLAY STREET, FIFTH FLOOR, OAKLAND CA 94612
Georgianna Maule-ffinch 2015 Trust	10 percent owner	C/O BETTER THERAPEUTICS, INC., 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Mark Heinen	officer: See Remarks	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Risa J Lavizzo-mourey	director	GE HEALTHCARE TECHNOLOGIES INC., 500 W. MONROE ST., CHICAGO IL 60661
Kevin J Appelbaum	director, 10 percent owner, officer: Chief Executive Officer	4160 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Suying Liu	director	311 WEST 43RD STREET, 12TH FLOOR, NEW YORK NY 10036
Justin Zamirowski	officer: Chief Commercial Officer	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Kristin Wynholds	officer: Chief Product Officer	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Richard H Carmona	director	1221 BROADWAY, OAKLAND CA 94612
David P. Perry 2015 Trust	10 percent owner	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104